Jakob Loven - Profile and Investment Details

Investor Profile

Jakob Loven is a Venture Capital, Private Equity Firm, Investor based in Sweden with a diverse investment portfolio that includes companies such as Black Diamond Therapeutics, Blueprint Medicines, Boundless Bio, Kronos Bio, Inc., TRACON Pharmaceuticals, Jounce Therapeutics, Kinnate Biopharma, Inc., Peloton Therapeutics, Arvinas, Cullinan Oncology, Silverback Therapeutics, Sunesis Pharmaceuticals, MolecularMD, MOMA Therapeutics, Scorpion Therapeutics, PMV Pharmaceuticals, Cleave Therapeutics, Vividion Therapeutics, Turning Point Therapeutics, Vividion Therapeutics. Inc., IDRx, ImaginAb, Autolus Ltd., Neon Therapeutics, A2 Biotherapeutics, Inc., Telormedix, Hexagon Bio, Ganymed Pharmaceuticals, Circle Pharma, Flare Therapeutics, EQRxKronos Bio, A2 Biotherapeutics, TetraLogic Pharmaceuticals, Kinnate Biopharma, Arrakis Therapeutics, Revolution Medicines, Kura Oncology, IconOVir Bio, IDEAYA Biosciences, Autolus, C4 Therapeutics, Agensys, Breakthrough Properties, . Over time, Jakob Loven has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Jakob Loven is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Life Science, Information Technology (IT), Biotechnology, Travel, Medical, Therapeutics, Media and Entertainment, Material Science, Pharmaceuticals may find it worthwhile to explore potential connections with Jakob Loven, as their portfolio suggests a familiarity and interest in this area.

Understanding Jakob Loven’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.